Centogene (NASDAQ:CNTG) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Centogene (NASDAQ:CNTG) released its quarterly earnings results on Monday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.10), Yahoo Finance reports. The business had revenue of $13.35 million during the quarter, compared to the consensus estimate of $13.78 million.

Centogene stock opened at $19.25 on Thursday. Centogene has a 1-year low of $7.80 and a 1-year high of $28.71. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 2.29. The stock has a market cap of $402.18 million and a PE ratio of -13.18. The stock’s fifty day moving average is $18.39 and its two-hundred day moving average is $15.09.

Several analysts have recently issued reports on the company. BTIG Research increased their price objective on Centogene from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Robert W. Baird increased their price objective on Centogene from $15.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, April 24th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.00.

About Centogene

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Further Reading: How can investors invest in the S&P/TSX Index?

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.